Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab

This open‐label, multicenter, phase I therapeutic protein‐drug interaction study was designed to evaluate the potential effect of guselkumab, a fully human anti‐interleukin‐23 immunoglobulin G1 lambda monoclonal antibody, on the pharmacokinetics of a cocktail of representative cytochrome P450 (CYP)...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yaowei, Xu, Yan, Zhuang, Yanli, Piantone, Alexa, Shu, Cathye, Chen, Dion, Zhou, Honghui, Xu, Zhenhua, Sharma, Amarnath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719363/
https://www.ncbi.nlm.nih.gov/pubmed/32407591
http://dx.doi.org/10.1111/cts.12807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719363/
https://www.ncbi.nlm.nih.gov/pubmed/32407591
http://dx.doi.org/10.1111/cts.12807

Ejemplares similares